Prevention of DNA damage and anticarcinogenic activity of Activia® in a preclinical model
| Autor: | S M A Limeiras, L A L Genez, Silvia Cordeiro das Neves, E J T Oliveira, Roberto Antoniolli da Silva, João Renato Pesarini, F M Ogo, C M Carreira, Lucas Roberto Pessatto, Wilson de Barros Cantero, A C M B Antoniolli-Silva, Rodrigo Juliano Oliveira, Laynna de Carvalho Schweich |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
DNA damage Colorectal cancer General Medicine Pharmacology Colorectal carcinogenesis Biology medicine.disease law.invention 03 medical and health sciences Probiotic 030104 developmental biology 0302 clinical medicine Intestinal mucosa law 030220 oncology & carcinogenesis Genetics medicine Molecular Biology Aberrant crypt foci |
| Zdroj: | Genetics and Molecular Research. 16 |
| ISSN: | 1676-5680 |
| DOI: | 10.4238/gmr16019492 |
| Popis: | Colorectal cancer is a global public health issue. Studies have pointed to the protective effect of probiotics on colorectal carcinogenesis. Activia® is a lacto probiotic product that is widely consumed all over the world and its beneficial properties are related, mainly, to the lineage of traditional yoghurt bacteria combined with a specific bacillus, DanRegularis, which gives the product a proven capacity to intestinal regulation in humans. The aim of this study was to evaluate the antigenotoxic, antimutagenic, and anticarcinogenic proprieties of the Activia product, in response to damage caused by 1,2-dimethylhydrazine (DMH) in Swiss mice. Activia does not have shown antigenotoxic activity. However, the percent of DNA damage reduction, evaluated by the antimutagenicity assay, ranged from 69.23 to 96.15% indicating effective chemopreventive action. Activia reduced up to 79.82% the induction of aberrant crypt foci by DMH. Facing the results, it is inferred that Activia facilitates the weight loss, prevents DNA damage and pre-cancerous lesions in the intestinal mucosa. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|